You are here: Home » Companies » News
Business Standard

Sun Pharma gets USFDA approval to produce cancer injection from Halol site

Halol's non-compliance has held up fresh product approvals from the site for nearly four years, and is partly responsible for the muted growth in the US for Sun.

Sohini Das  |  Mumbai 

Sun Pharma

on Wednesday announced that it received the first product approval from the US drug regulator filed from the (Gujarat), after the facility was cleared last month.

Halol’s non-compliance has held up fresh product approvals from the site for nearly four years, and is partly responsible for the muted growth in the US for Sun.

It received the nod for an oncology injectable Infugem to be manufactured at the Gujarat facility.

The drug has an addressable market size of approximately $35 million for the 12 months ending March 2018, as per IQVIA.

The Halol unit received Establishment Inspection Report (EIR) last month, that brought to closure the three-year long regulatory hurdle the plant was facing with the (USFDA).

The regulator had inspected the plant in 2014 and issued a warning letter in December 2015, following which could not file for fresh approvals from the site.


In June, the USFDA closed the inspection, paving way for fresh approvals. said, “The approval means the plant is fully functional and we can see many such approvals from this plant. Due to compliance issues and warning letter on this facility, several product approvals were blocked by the USFDA."

Analysts feel Halol’s resolution could add as much as $100 million in revenues annually.

Abhay Gandhi, chief executive officer (North America region), said: “We’re pleased to add this novel product to our expanding oncology portfolio as gemcitabine is one of the most commonly used cytotoxics in oncology practice.”

First Published: Wed, July 18 2018. 21:52 IST
RECOMMENDED FOR YOU